【24h】

Prostatic ductal adenocarcinoma showing Bcl-2 expression.

机译:前列腺导管腺癌显示Bcl-2表达。

获取原文
获取原文并翻译 | 示例
       

摘要

Prostatic ductal adenocarcinoma represents a rare histological variant of prostatic carcinoma with features of a papillary lesion at cystoscopy. There are conflicts regarding the existence, origin, staging, grading, treatment and clinical behavior of this tumor. The aim of the present study is to examine the expression of Bcl-2 and p53 in prostatic ductal adenocarcinoma and to evaluate its origin by analyzing prostate specific antigen, prostate specific acid phosphatase, cytokeratins, epithelial membrane antigen and carcinoembryonic antigen expressions. The results confirmed the expression of prostate specific antigen and prostate specific acid phosphatase in prostatic ductal adenocarcinoma. The demonstrated expression of Bcl-2 was predominant in the better-differentiated tumor. Bcl-2 expression appears not to be associated with neuroendocrine differentiation as assessed by chromogranin A reactivity. Thus, the first case of a prostatic ductal adenocarcinoma showing Bcl-2 expression is presented. The tumor was negative for p53.
机译:前列腺导管腺癌代表了一种罕见的前列腺癌组织学变体,在膀胱镜检查中具有乳头状病变的特征。关于该肿瘤的存在,起源,分期,等级,治疗和临床行为存在冲突。本研究的目的是检查前列腺癌中Bcl-2和p53的表达,并通过分析前列腺特异性抗原,前列腺特异性酸性磷酸酶,细胞角蛋白,上皮膜抗原和癌胚抗原表达来评估其起源。结果证实了前列腺特异性抗原和前列腺特异性酸性磷酸酶在前列腺导管腺癌中的表达。 Bcl-2的表达在分化较好的肿瘤中占主导。通过嗜铬粒蛋白A反应性评估,Bcl-2表达似乎与神经内分泌分化无关。因此,提出了第一例显示Bcl-2表达的前列腺导管腺癌。肿瘤p53阴性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号